Skip to main content
. 2003 Oct 14;89(8):1439–1444. doi: 10.1038/sj.bjc.6601310

Table 3. Repartition of oxaliplatin or irinotecan chemotherapy line.

Chemotherapy line All patients, n=66 (%) Group 1, n=48 (%) Group 2, n=18 (%)
 First line 27 (41) 20 (42) 7 (39)
 Oxaliplatin 19 14 5
 Irinotecan 8 6 2
       
Second line 34 (51) 26 (54) 8 (44)
 Oxaliplatin 21 17 4
 Irinotecan 13 9 4
       
Third line 5 (8) 2 (4) 3 (17)
 Oxaliplatin 4 2 2
 Irinotecan 1 1